株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

基底細胞癌 (基底細胞上皮腫):パイプライン製品の分析

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 227551
出版日 ページ情報 英文 112 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
基底細胞癌 (基底細胞上皮腫):パイプライン製品の分析 Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 112 Pages
概要

基底細胞癌とは、基底細胞から発症する皮膚病の一種です。主な症状には、蝋状の瘤や、黒褐色のかさぶた、白い蝋状の瘢痕などが挙げられます。疾病素質には年齢や家族歴、放射線への被爆、免疫抑制療法などがあります。主な治療法には化学療法や外科手術などがあります。

当レポートでは、世界各国での基底細胞癌 (基底細胞上皮腫) 治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

基底細胞癌 (基底細胞上皮腫) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

基底細胞癌 (基底細胞上皮腫):企業で開発中の治療薬

基底細胞癌 (基底細胞上皮腫):大学/機関で研究中の治療薬

基底細胞癌 (基底細胞上皮腫):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

基底細胞癌 (基底細胞上皮腫):企業で開発中の製品

基底細胞癌 (基底細胞上皮腫):大学/機関で研究中の製品

基底細胞癌 (基底細胞上皮腫) の治療薬開発に従事している企業

  • Biofrontera AG
  • Biosceptre (Aust) Pty Ltd
  • Genextra S.p.a.
  • Ignyta, Inc.
  • Laboratories Ojer Pharma S.L.
  • MediGene AG
  • Merck & Co., Inc.
  • Novartis AG
  • Provectus Biopharmaceuticals, Inc.
  • Redx Pharma Plc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Transgene SA

基底細胞癌 (基底細胞上皮腫):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

基底細胞癌 (基底細胞上皮腫):最近のパイプライン動向

基底細胞癌 (基底細胞上皮腫):休止中のプロジェクト

基底細胞癌 (基底細胞上皮腫):開発が中止された製品

基底細胞癌 (基底細胞上皮腫):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8576IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H2 2016, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 5, 2 and 6 respectively for Basal Cell Carcinoma.

Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Basal Cell Carcinoma (Basal Cell Epithelioma) Overview
  • Therapeutics Development
    • Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
    • Biofrontera AG
    • Biosceptre (Aust) Pty Ltd
    • Cannabis Science, Inc
    • Genextra S.p.a.
    • Ignyta, Inc.
    • Laboratories Ojer Pharma S.L.
    • MediGene AG
    • Merck & Co., Inc.
    • PellePharm, Inc.
    • Provectus Biopharmaceuticals, Inc.
    • Redx Pharma Plc
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    • Transgene SA
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • aminolevulinic acid hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • aminolevulinic acid hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIL-010t - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BLR-300 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CS-S/BCC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CSTATI-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DAC-060 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oshadi D + Oshadi R - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patidegib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PV-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sinecatechins - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taladegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-1042 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 28, 2016: Biofrontera Receives Favourable CHMP Assessment for Field-Directed Therapy and Files BCC Application
      • Jun 23, 2016: Biofrontera Progresses with Expansion of U.S. Subsidiary with Key Personnel Hires
      • Nov 19, 2015: Biofrontera reports final patient visit in phase III trial for basal cell carcinoma
      • Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
      • Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi's Sarcoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre (Aust) Pty Ltd, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science, Inc, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra S.p.a., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta, Inc., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma S.L., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co., Inc., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by PellePharm, Inc., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Redx Pharma Plc, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2016
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top